TY - JOUR
T1 - Inhaled nitric oxide for treating pain crises in people with sickle cell disease
AU - Altawashi, Abdulkareem
AU - Albaroudi, Omar
AU - Aboursheid, Tarek
AU - Alahdab, Fares
N1 - Funding Information:
We will identify relevant trials from the Cystic Fibrosis and Genetic Disorders Group’s Haemoglobinopathies Trials Register using the terms: (sickle cell OR (haemoglobinopathies AND general)) AND nitric oxide. The Haemoglobinopathies Trials Register is compiled from electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL) (updated each new issue of The Cochrane Library) and weekly searches of MEDLINE. Unpublished work is identified by searching the abstract books of five major conferences: the European Haematology Association conference; the American Society of Hematology conference; the British Society for Haematology Annual Scientific Meeting; the Caribbean Health Research Council Meetings; and the National Sickle Cell Disease Program Annual Meeting. For full details of all searching activities for the register, please see the relevant section of the Cochrane Cystic Fibrosis and Genetic Disorders Group Module.
Funding Information:
• National Institute for Health Research, UK. This systematic review was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to the Cochrane Cystic Fibrosis and Genetic Disorders Group.
Publisher Copyright:
© 2015 The Cochrane Collaboration.
PY - 2015/7/22
Y1 - 2015/7/22
N2 - This is the protocol for a review and there is no abstract. The objectives are as follows: To capture the available body of evidence that evaluates the efficacy and safety of the use of iNO in treating pain crises in people with SCD; and to assess the treatment's relevance, robustness, and validity, in order to better guide medical practice in the fields of haematology and palliative care (since recent literature seems to favour the involvement of palliative care for those people).
AB - This is the protocol for a review and there is no abstract. The objectives are as follows: To capture the available body of evidence that evaluates the efficacy and safety of the use of iNO in treating pain crises in people with SCD; and to assess the treatment's relevance, robustness, and validity, in order to better guide medical practice in the fields of haematology and palliative care (since recent literature seems to favour the involvement of palliative care for those people).
UR - http://www.scopus.com/inward/record.url?scp=85041845992&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85041845992&partnerID=8YFLogxK
U2 - 10.1002/14651858.CD011808
DO - 10.1002/14651858.CD011808
M3 - Article
AN - SCOPUS:85041845992
VL - 2015
JO - The Cochrane database of systematic reviews
JF - The Cochrane database of systematic reviews
SN - 1469-493X
IS - 7
M1 - CD011808
ER -